Literature DB >> 22640710

Ovarian cancer: screening and early detection.

Barbara A Goff1.   

Abstract

Ultimately, the timely diagnosis of ovarian cancer will rely on clinical judgment and careful analysis of presenting symptoms within the context of a thoughtful dialogue between the patient and her physician. Symptoms most typical of ovarian cancer include bloating, abdominal or pelvic pain, and difficulty eating. In some studies, urinary symptoms are also a common presenting symptom. When these symptoms occur more than 12 times per month and are of recent onset, then ovarian cancer should be considered as a possibility. Although most women who have these symptoms do not have ovarian cancer, it is important that providers include ovarian cancer in their differential diagnosis. Through research from the past decade, we now understand that there are patterns of symptoms associated with ovarian cancer. Importantly, we now know that ovarian cancer is not a “silent disease.” Finally, clinicians must always listen carefully to their patients avoid potentially harmful delays in diagnosis. Until there is a screening test, awareness is best.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22640710     DOI: 10.1016/j.ogc.2012.02.007

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  9 in total

1.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

Review 2.  Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives.

Authors:  Xiao-Mei Zhou; Hai Zhang; Xia Han
Journal:  Tumour Biol       Date:  2014-08-29

3.  Clear cell ovarian cancer and endometriosis: is there a relationship?

Authors:  Maria Szubert; Jacek Suzin; Katarzyna Obirek; Amanda Sochacka; Marta Łoszakiewicz
Journal:  Prz Menopauzalny       Date:  2016-07-22

4.  Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.

Authors:  Janusz Menkiszak; Anita Chudecka-Głaz; Jacek Gronwald; Aneta Cymbaluk-Płoska; Aleksander Celewicz; Maria Świniarska; Małgorzata Wężowska; Ryszard Bedner; Dorota Zielińska; Paulina Tarnowska; Jerzy Jakubowicz; Zbigniew Kojs
Journal:  J Ovarian Res       Date:  2016-02-29       Impact factor: 4.234

5.  Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression.

Authors:  Jie Qin; Yan Liu; Yongkui Lu; Meiling Liu; Manli Li; Juan Li; Lijuan Wu
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

6.  Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.

Authors:  Janusz Menkiszak; Anita Chudecka-Głaz; Aneta Cymbaluk-Płoska; Aleksander Celewicz; Zbigniew Kojs; Mariusz Szajda; Maria Świniarska; Ryszard Bedner; Anna Jurczak; Marta Celewicz; Monika Cieszyńska; Jan Lubiński; Jacek Gronwald
Journal:  Hered Cancer Clin Pract       Date:  2019-03-14       Impact factor: 2.857

7.  Suppression of GNAI2 message in ovarian cancer.

Authors:  John R Raymond; Kathryn M Appleton; Jennifer Y Pierce; Yuri K Peterson
Journal:  J Ovarian Res       Date:  2014-01-14       Impact factor: 4.234

8.  Double agents: genes with both oncogenic and tumor-suppressor functions.

Authors:  Libing Shen; Qili Shi; Wenyuan Wang
Journal:  Oncogenesis       Date:  2018-03-13       Impact factor: 7.485

9.  Identification of Hypoxia Signature to Assess the Tumor Immune Microenvironment and Predict Prognosis in Patients with Ovarian Cancer.

Authors:  Chunyan Wei; Xiaoqing Liu; Qin Wang; Qipei Li; Min Xie
Journal:  Int J Endocrinol       Date:  2021-12-14       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.